Pfizer (NYSE:PFE) Trading Up 1.3% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) traded up 1.3% during mid-day trading on Tuesday . The stock traded as high as $24.35 and last traded at $24.0370. Approximately 43,867,471 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 42,799,309 shares. The stock had previously closed at $23.72.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is being highlighted by multiple articles as a “dirt cheap” healthcare name, which may be attracting value investors looking for cash-generating stocks with low valuations. 2 Dirt Cheap Healthcare Stocks to Buy in July
• Positive Sentiment: Pfizer recently won FDA approval for IBRANCE in a new breast cancer indication, a reminder that the company still has pipeline and label-expansion catalysts that can support long-term revenue. Pfizer (PFE) Wins FDA Approval For IBRANCE In HER2 Positive Breast Cancer
• Positive Sentiment: Cantor Fitzgerald reaffirmed a neutral view but set a $27 price target, implying upside from recent trading levels and offering some support to the shares. Benzinga coverage of Cantor Fitzgerald rating
• Neutral Sentiment: Pfizer is also being compared with AstraZeneca in a long-term growth debate, with analysts favoring AstraZeneca on key growth metrics, which keeps Pfizer’s relative valuation and pipeline story under scrutiny. Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
• Negative Sentiment: Analysts downgraded Pfizer to Hold, citing delayed pipeline catalysts, leadership changes, and less near-term re-rating potential. Pfizer’s Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
• Negative Sentiment: Separately, commentary warned that Pfizer’s dividend could be riskier than it looks, which may raise concerns for income-focused shareholders. Opinion: Pfizer’s Dividend Is Riskier Than You Might Think

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. UBS Group reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday. CICC Research started coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Citigroup upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Finally, Guggenheim lifted their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.59.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock’s fifty day moving average price is $25.63 and its 200-day moving average price is $26.23. The firm has a market cap of $137.00 billion, a PE ratio of 18.35 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer’s dividend payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Horizon Financial Services LLC lifted its stake in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer in the fourth quarter worth $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer in the fourth quarter valued at $28,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Finally, Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.